Number of patients with nonhematologic adverse events CTC grade 3 or 4 (percentages), by daily dose cytarabine and by cycle number
| Adverse event . | Cytarabine 200 mg/m2, dose levels I, II, IIIA, IVA . | Cytarabine 1000 mg/m2, dose levels IIIB, IVB, V . | ||
|---|---|---|---|---|
| Cycle 1, n = 107 (%) . | Cycle 2, n = 96 (%) . | Cycle 1, n = 55 (%) . | Cycle 2, n = 44 (%) . | |
| Any | 23 (21) | 14 (15) | 14 (25) | 11 (25) |
| Hemorrhage | 8 (7) | 5 (5) | 3 (5) | 1 (2) |
| Neurology | 4 (4) | 1 (1) | 3 (5) | 1 (2) |
| Hepatic | 2 (2) | 2 (2) | 3 (5) | 1 (2) |
| Pain | 8 (7) | 1 (1) | 3 (5) | 2 (5) |
| Cardiovascular function | 1 (1) | 1 (1) | 2 (4) | 2 (5) |
| Constitutional symptoms | 1 (1) | 1 (1) | 1 (2) | 3 (7) |
| Dermatology/skin | 0 | 4 (4) | 2 (4) | 0 |
| Gastrointestinal | 2 (2) | 1 (1) | 3 (5) | 4 (9) |
| Metabolic | 1 (1) | 0 | 1 (2) | 0 |
| Pulmonary | 1 (1) | 0 | 1 (2) | 1 (2) |
| Allergy/immunology | 2 (2) | 0 | 1 (2) | 0 |
| Genitourinary and renal | 0 | 0 | 1 (2) | 0 |
| Adverse event . | Cytarabine 200 mg/m2, dose levels I, II, IIIA, IVA . | Cytarabine 1000 mg/m2, dose levels IIIB, IVB, V . | ||
|---|---|---|---|---|
| Cycle 1, n = 107 (%) . | Cycle 2, n = 96 (%) . | Cycle 1, n = 55 (%) . | Cycle 2, n = 44 (%) . | |
| Any | 23 (21) | 14 (15) | 14 (25) | 11 (25) |
| Hemorrhage | 8 (7) | 5 (5) | 3 (5) | 1 (2) |
| Neurology | 4 (4) | 1 (1) | 3 (5) | 1 (2) |
| Hepatic | 2 (2) | 2 (2) | 3 (5) | 1 (2) |
| Pain | 8 (7) | 1 (1) | 3 (5) | 2 (5) |
| Cardiovascular function | 1 (1) | 1 (1) | 2 (4) | 2 (5) |
| Constitutional symptoms | 1 (1) | 1 (1) | 1 (2) | 3 (7) |
| Dermatology/skin | 0 | 4 (4) | 2 (4) | 0 |
| Gastrointestinal | 2 (2) | 1 (1) | 3 (5) | 4 (9) |
| Metabolic | 1 (1) | 0 | 1 (2) | 0 |
| Pulmonary | 1 (1) | 0 | 1 (2) | 1 (2) |
| Allergy/immunology | 2 (2) | 0 | 1 (2) | 0 |
| Genitourinary and renal | 0 | 0 | 1 (2) | 0 |
CTC indicates common toxicity criteria.